Medicare Procedure and Patient Information
2020 Medicare Patient Data
Information about Medicare patients treated by Dr. Willis H. Navarro, MD.
| Non-Hispanic White | |
|---|---|
| Black | |
| Hispanic | |
| Asian | |
| Other | |
| Native American |
(No ratings)
Dr. Willis H. Navarro, MD is a medical oncologist in Tucson, AZ specializing in medical oncology, physician and hematology (blood disorders). Dr. Willis H. Navarro, MD is affiliated with Banner - University Medical Group (BUMG), The University of Arizona Cancer Center and University of Arizona Cancer Center.
Information about Medicare patients treated by Dr. Willis H. Navarro, MD.
| Non-Hispanic White | 11 |
|---|---|
| Black | 0 |
| Hispanic | 0 |
| Asian | 0 |
| Other | 0 |
| Native American | 0 |
| Hypertension | 75 |
|---|---|
| High Cholesterol | 61 |
| Stroke | 0 |
| Ischemic Heart Disease | 61 |
| Depression | 0 |
| Chronic Kidney Disease | 72 |
| Asthma | 0 |
| Osteoperosis | 0 |
| Atrial Fibrilation | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Dementia | 0 |
| Cancer | 0 |
Volume of procedures performed by Dr. Willis H. Navarro, MD for Medicare patients.
| doctor visit | 16 |
|---|
| Hypertension | 75 |
|---|---|
| High Cholesterol | 75 |
| Stroke | 0 |
| Ischemic Heart Disease | 0 |
| Depression | 0 |
| Chronic Kidney Disease | 0 |
| Asthma | 0 |
| Osteoperosis | 0 |
| Atrial Fibrilation | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Dementia | 0 |
| Cancer | 0 |
| Hypertension | 75 |
|---|---|
| High Cholesterol | 75 |
| Stroke | 0 |
| Ischemic Heart Disease | 0 |
| Depression | 0 |
| Chronic Kidney Disease | 0 |
| Asthma | 0 |
| Osteoperosis | 0 |
| Atrial Fibrilation | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Dementia | 0 |
| Cancer | 0 |
Volume of procedures performed by Dr. Willis H. Navarro, MD for Medicare patients.
| doctor visit | 16 |
|---|
Information about Medicare patients treated by Dr. Willis H. Navarro, MD.
| Black / African American | 0 |
|---|---|
| Asian / Pacific Islander | 0 |
| Non-Hispanic White | 2 |
| Hispanic | 0 |
| Native American / Alaskan Native | 0 |
| Other | 0 |
The highest averages of the most common conditions of Medicare patients that Dr. Willis H. Navarro, MD treated were hypertension, high cholesterol, chronic kidney disease and ischemic heart disease.
| Hypertension | 56 |
|---|---|
| High Cholesterol | 52 |
| Stroke | 0 |
| Ischemic Heart Disease | 15 |
| Depression | 0 |
| Chronic Kidney Disease | 18 |
| Asthma | 0 |
| Osteoporosis | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Atrial Fibrillation | 0 |
| Dementia | 0 |
| Cancer | 0 |
He completed residency at Yale New Haven Medical Center. He has a state license in Arizona.
Residency: Yale New Haven Medical Center (1993)
Licensed In: Arizona
Dr. Willis H. Navarro, MD does not have any reviews yet, be the first to leave a review of Dr. Willis H. Navarro, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Willis H. Navarro, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| Pfizer Inc. |
$266
$266 |
|
|---|---|---|
| Incyte Corporation |
$203
MONJUVI $110 |
$93 |
| Amgen Inc. |
$143
$143 |
|
| Celgene Corporation |
$118
$118 |
|
| Merck Sharp & Dohme Corporation |
$42
KEYTRUDA $42 |
|
| Other |
$27
Venclexta $27 |
| Food and Beverage | $440 |
|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $266 |
| Education | $93 |
Patient-based: -Patient involvement, education, and empowerment -Respect for diversity, differences in experiences, and viewpoints -Mutual goal setting and decision-making Teams-based Knowledge-based -Maintaining state-of-art standards of treatment and care through ongoing acquisition of the latest information about hematologic cancers -Participation in clinical trials when appropriate